文献速递临床试验与 GCP

根据出血风险决定经皮冠状动脉介入术后双联抗血小板治疗疗程(HOST-BR):一项开放标签、多中心、随机临床试验

Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
PubMed 文献 · Lancet · 2025-10-23

HOST-BR研究在韩国50个高容量心脏中心纳入4897例药物洗脱支架PCI术后患者,按ARC-HBR标准分为高出血风险(HBR)和非HBR层。HBR层1个月DAPT对比3个月DAPT未达到净不良临床事件非劣效;非HBR层3个月DAPT对比12个月DAPT在净不良临床事件和大心血管脑事件上非劣效,出血更少。

要点

  • HBR患者1个月DAPT对比3个月DAPT未达到净不良临床事件非劣效(HR 1.337,95%CI 1.043-1.713;非劣效p=0.82)。
  • 非HBR患者3个月DAPT对比12个月DAPT净不良临床事件非劣效(HR 0.657,95%CI 0.455-0.949;非劣效p<0.0001)。
  • 非HBR患者3个月DAPT对比12个月DAPT出血更优(HR 0.631,95%CI 0.502-0.793;p<0.0001)。

核心结论

  • 在东亚HBR患者中,1个月DAPT对比3个月DAPT未达到净不良临床事件非劣效。
  • 在非HBR患者中,3个月DAPT对比12个月DAPT在净不良临床事件和大心血管脑事件上非劣效,出血更优。

研究设计与样本

  • 开放标签、多中心、随机临床试验,在韩国50个高容量心脏中心纳入年龄19岁及以上接受药物洗脱支架PCI的患者。
  • 按ARC-HBR标准分层为HBR或非HBR;HBR层随机1:1分配至1个月或3个月DAPT,非HBR层随机1:1分配至3个月或12个月DAPT。
  • 共纳入4897例患者(HBR层1598例,非HBR层3299例),纳入时间为2020年7月24日至2023年9月25日。

主要发现

  • HBR层1个月DAPT组净不良临床事件144/798例(18.4%)vs 3个月DAPT组110/800例(14.0%),HR 1.337(95%CI 1.043-1.713),非劣效p=0.82。
  • HBR层大心血管脑事件1个月DAPT组74例(9.8%)vs 3个月DAPT组44例(5.8%);出血1个月DAPT组105例(13.8%)vs 3个月DAPT组122例(15.8%)。
  • 非HBR层3个月DAPT组净不良临床事件47/1649例(2.9%)vs 12个月DAPT组72/1650例(4.4%),HR 0.657(95%CI 0.455-0.949),非劣效p<0.0001。
  • 非HBR层大心血管脑事件3个月DAPT组36例(2.2%)vs 12个月DAPT组37例(2.3%),HR 0.984(95%CI 0.622-1.558),非劣效p=0.0082。
  • 非HBR层出血3个月DAPT组120例(7.4%)vs 12个月DAPT组190例(11.7%),HR 0.631(95%CI 0.502-0.793),p<0.0001。

关键数值与推荐

  • HBR分层依据ARC-HBR标准;主要终点为随机化后1年的净不良临床事件、大心血管脑事件和任何可操作的非手术出血。
  • HBR层1个月DAPT对比3个月DAPT净不良临床事件未达非劣效(HR 1.337,95%CI 1.043-1.713;非劣效p=0.82)。
  • 非HBR层3个月DAPT对比12个月DAPT净不良临床事件非劣效(HR 0.657,95%CI 0.455-0.949;非劣效p<0.0001)。
  • 非HBR层3个月DAPT对比12个月DAPT大心血管脑事件非劣效(HR 0.984,95%CI 0.622-1.558;非劣效p=0.0082)。
  • 非HBR层3个月DAPT对比12个月DAPT出血更优(HR 0.631,95%CI 0.502-0.793;p<0.0001)。

临床怎么用

  • 在东亚HBR患者中,1个月DAPT未达到净不良临床事件非劣效于3个月DAPT。
  • 在非HBR患者中,3个月DAPT在净不良临床事件和大心血管脑事件上非劣效于12个月DAPT,且出血更少。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after coronary stenting according to bleeding risk is not well established. We aimed to evaluate the optimal duration of DAPT after coronary stenting according to bleeding risk. METHODS: In this open-label, multicentre, randomised clinical trial, patients aged 19 years and older who received percutaneous coronary intervention with a drug-eluting stent at 50 high-volume cardiology centres in South Korea were stratified into high bleeding risk (HBR) or non-HBR strata, according to Academic Research Consortium for High Bleeding Risk criteria. Patients in the HBR stratum were randomly assigned (1:1) to 1-month or 3-month DAPT, and those in the non-HBR stratum were randomly assigned (1:1) to 3-month or 12-month DAPT. The three coprimary endpoints were net adverse clinical events (all-cause death, myocardial infarction, stent thrombosis, stroke, or major bleeding), major adverse cardiac or cerebral events (cardiovascular death, myocardial infarction, definite or probable stent thrombosis, or ischaemic stroke), and any actionable non-surgical bleeding at 1 year after randomisation. Primary endpoints were assessed in hierarchical order in the intention-to-treat population. This study is registered with cris.nih.go.kr, KCT0005356, and ClinicalTrials.gov, NCT05631769, and is complete. FINDINGS: From July 24, 2020, to Sept 25, 2023, 4897 patients were enrolled (1598 in the HBR stratum and 3299 in the non-HBR stratum). In the HBR stratum, 1-month compared with 3-month DAPT did not reach non-inferiority for net adverse clinical events (144 [18·4%] of 798 vs 110 [14·0%] of 800 patients; hazard ratio [HR] 1·337 [95% CI 1·043-1·713]; p=0·82 for non-inferiority). Major adverse cardiac or cerebral events occurred in 74 (9·8%) patients in the 1-month DAPT group and 44 (5·8%) in the 3-month group; bleeding occurred in 105 (13·8%) patients in the 1-month group and 122 (15·8%) in the 3-month group. In the non-HBR stratum, 3-month was non-inferior to 12-month DAPT regarding net adverse clinical events (47 [2·9%] of 1649 vs 72 [4·4%] of 1650 patients; HR 0·657 [0·455-0·949]; p<0·0001 for non-inferiority) and major adverse cardiac or cerebral events (36 [2·2%] vs 37 [2·3%]; HR 0·984 [0·622-1·558]; p=0·0082 for non-inferiority), and superior for bleeding (120 [7·4%] vs 190 [11·7%]; HR 0·631 [0·502-0·793]; p<0·0001). INTERPRETATION: In east Asian patients with HBR, 1-month DAPT did not reach non-inferiority to 3-month DAPT for net adverse clinical events. In patients without HBR, 3-month DAPT was non-inferior to 12-month DAPT regarding net adverse clinical events and major adverse cardiac or cerebral events, and superior for bleeding. FUNDING: Medtronic and Abbott.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Kang J, Park KW, Han JK, et al. Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial. Lancet. 2025. PMID: 41631724. doi:10.1016/S0140-6736(25)01571-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。